They might have decreased kidney function, drug interactions, and more malabsorption issues
Vascular and Angiogenic Effects BPC-157 functions as a potent angiomodulatory agent, optimizing vascular responses across diverse injury contexts
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
youtube.com/watch?v=AxKEJQg
If your thyroid status is unstable or you are adjusting medication, this is not the ideal time to add peptides